Skip to content

Aptamarkers

Use of aptamer libraries for biomarker discovery

Biomarker Discovery

The NeoVentures invention of reproducible aptamer selection with the Neomer platform enables a novel and powerful application for biomarker discovery for any disease or condition. For the first time it is possible to screen the same library of aptamers for their selection response to biological fluids or tissue from individuals that differ in their medical condition. With the Aptamarker platform we harness this power to screen for quantitative differences in 4.29E9 potential epitopes per sample. This is an unprecedented step forward in magnitude for agnostic identification of molecular differences as they relate to any characterized phenotype.

4.29 billion aptamers screened on each sample

Biomarker Discovery

The NeoVentures invention of reproducible aptamer selection with the Neomer platform enables a novel and powerful application for biomarker discovery for any disease or condition. For the first time it is possible to screen the same library of aptamers for their selection response to biological fluids or tissue from individuals that differ in their medical condition. With the Aptamarker platform we harness this power to screen for quantitative differences in 4.29E9 potential epitopes per sample. This is an unprecedented step forward in magnitude for agnostic identification of molecular differences as they relate to any characterized phenotype.

4.29 billion aptamers screened on each sample

Paradigm Shift for Biomarker Discovery

  • Proteomics limited to 2,000 proteins
  • Quantitative metabolomics limited to less
  • Antibody based approaches non-quantitative in discovery

 

Aptamarkers 4.29E9 epitopes screened per sample (fluid or tissue)

Proof of Concept with First Use Case (prediction of brain amyloid from plasma analysis)

Paradigm Shift for Biomarker Discovery

  • Proteomics limited to 2,000 proteins
  • Quantitative metabolomics limited to less
  • Antibody based approaches non-quantitative in discovery

 

Aptamarkers 4.29E9 epitopes screened per sample (fluid or tissue)

Proof of Concept with First Use Case (prediction of brain amyloid from plasma analysis)

Aptamarker Applications

  1. Biomarkers in biofluids for any disease
    • Agnostic screening with capacity to characterize targets of biomarkers
  2. Patient stratification
    • Exclusion (identification of patients with predisposition to side effects or lack of response)
    • Inclusion (enrollment of patients with predisposition for treatment response)
  3. Off-target toxicity prediction
    • Prediction of side effect response
    • Translation from animal models
  4. Target engagement characterization
    • Mapping drug binding sites
    • Developing dynamic tests for on/off rates
  5. Replace proteomics
    • All proteins and complexes all at once

Aptamarker Applications

  1. Biomarkers in biofluids for any disease
    • Agnostic screening with capacity to characterize targets of biomarkers
  2. Patient stratification
    • Exclusion (identification of patients with predisposition to side effects or lack of response)
    • Inclusion (enrollment of patients with predisposition for treatment response)
  3. Off-target toxicity prediction
    • Prediction of side effect response
    • Translation from animal models
  4. Target engagement characterization
    • Mapping drug binding sites
    • Developing dynamic tests for on/off rates
  5. Replace proteomics
    • All proteins and complexes all at once

Use Cases

1. Inclusion/Exclusion criteria for clinical trials

 The performance of a clinical trial generates new information. Certain individuals within the trial may exhibit undesirable side effects or fail to respond to treatment. Others may respond to treatment better than expected with no deleterious side effects. The Aptamarker platform allows the training of Aptamarkers to predict individual clinical trial outcomes. This requires application of the Aptamarker library to biological samples from the individuals entering a clinical trial prior to the application of the treatment, and it requires knowledge of such individuals reaction to treatment. 

The translation of Aptamarkers arising from this type of training to a simple qPCR test enables cost-effective screening of individuals for clinical trial enrollment either on the basis of exclusion or inclusion. This approach also enables reposition of clinical trials for different indications. 

Use Cases

1. Inclusion/Exclusion criteria for clinical trials

 The performance of a clinical trial generates new information. Certain individuals within the trial may exhibit undesirable side effects or fail to respond to treatment. Others may respond to treatment better than expected with no deleterious side effects. The Aptamarker platform allows the training of Aptamarkers to predict individual clinical trial outcomes. This requires application of the Aptamarker library to biological samples from the individuals entering a clinical trial prior to the application of the treatment, and it requires knowledge of such individuals reaction to treatment. 

The translation of Aptamarkers arising from this type of training to a simple qPCR test enables cost-effective screening of individuals for clinical trial enrollment either on the basis of exclusion or inclusion. This approach also enables reposition of clinical trials for different indications. 

2. Stratification of patients within a disease

We use all of the information from the Aptamarker analysis across individuals to build a molecular space which we can observe clustering of the individuals. The identification of these clusters provides a basis for characterizing different pathophysiological processes that lead to the same phenotype. 

We can also include clinical variables such as comorbidities, sex and age as additional variables and add this information to the overall information space. 

Our capacity to convert Aptamarkers into simple qPCR tests also means that we can construct a scaffold of this molecular characterization space with a subset of Aptamarkers. This scaffold can then be used as a basis for patient stratification on a clinical level for diagnosis or treatment streaming. It requires considerable work to build the molecular characterization space, but once it is built future individuals can be positioned within it with a qPCR test with a minimal number of Aptamarkers. 

In the graph that follows we show an abstract example of such a space for any disease. The different colours could represent different aspects of a clinical variable such as age, or different outcomes from a common disease. 

Translation of biomarkers from animals to humans

The lack of immune tolerance with Aptamarker development means that Aptamarkers detect orthologous epitopes that would be eliminated in antibody development. This means that there will be more Aptamarkers that bind to a given biomarker than antibodies, resulting in more opportunity for translation between animal trials and human trials. 

Aptamarkers can be trained in animal trials and screened for efficacy in preparation for human trials. This can be used to ensure earlier screening for treatment effects.

The Aptamarker platform represents a new science. We welcome your thoughts and ideas on other potential applications of this technology. We are committed to working with partners collaboratively to apply this technology to help you solve problems. 

To learn more:

The Aptamarker platform is available exclusively through NeoVentures Biotechnology Europe.

Please contact us to discuss:

  • Applications to your specific projects
  • Incorporation of approach in grant proposals
  • Additional use cases

2. Stratification of patients within a disease

We use all of the information from the Aptamarker analysis across individuals to build a molecular space which we can observe clustering of the individuals. The identification of these clusters provides a basis for characterizing different pathophysiological processes that lead to the same phenotype. 

We can also include clinical variables such as comorbidities, sex and age as additional variables and add this information to the overall information space. 

Our capacity to convert Aptamarkers into simple qPCR tests also means that we can construct a scaffold of this molecular characterization space with a subset of Aptamarkers. This scaffold can then be used as a basis for patient stratification on a clinical level for diagnosis or treatment streaming. It requires considerable work to build the molecular characterization space, but once it is built future individuals can be positioned within it with a qPCR test with a minimal number of Aptamarkers. 

In the graph that follows we show an abstract example of such a space for any disease. The different colours could represent different aspects of a clinical variable such as age, or different outcomes from a common disease. 

Translation of biomarkers from animals to humans

The lack of immune tolerance with Aptamarker development means that Aptamarkers detect orthologous epitopes that would be eliminated in antibody development. This means that there will be more Aptamarkers that bind to a given biomarker than antibodies, resulting in more opportunity for translation between animal trials and human trials. 

Aptamarkers can be trained in animal trials and screened for efficacy in preparation for human trials. This can be used to ensure earlier screening for treatment effects.

The Aptamarker platform represents a new science. We welcome your thoughts and ideas on other potential applications of this technology. We are committed to working with partners collaboratively to apply this technology to help you solve problems. 

To learn more:

The Aptamarker platform is available exclusively through NeoVentures Biotechnology Europe.

Please contact us to discuss:

  • Applications to your specific projects
  • Incorporation of approach in grant proposals
  • Additional use cases

Licensing Opportunities

We have decided to make the Neomer library available for licensing to labs that have the capacity for selection in-house. This route offers substantial savings over our traditional custom aptamer design. Find out more about licensing.

Licensing Opportunities

We have decided to make the Neomer library available for licensing to labs that have the capacity for selection in-house. This route offers substantial savings over our traditional custom aptamer design. Find out more about licensing.

Start Now with a Free Consultation

Start Now with a Free Consultation

Watch Dr. Gregory Penner's Presentation

Neomers:
A Reproducible Aptamer Selection Method

This conference took place on April 4th at Aptamers 2022.

Dr. Gregory Penner introduced our game-changing new method of aptamer selection. Hear what he has to say about it by watching the full presentation.

Fill in the form for instant access.

Get Instant Access Now

Watch Dr. Gregory Penner's Presentation

Neomers:
A Reproducible Aptamer Selection Method

This conference took place on April 4th at Aptamers 2022.

Dr. Gregory Penner introduced our game-changing new method of aptamer selection. Hear what he has to say about it by watching the full presentation.

Fill in the form for instant access.

Get Instant Access Now